Archives of Sexual Behavior

, Volume 22, Issue 6, pp 521–543 | Cite as

Prosexual drugs: Empirical status of the “new aphrodisiacs”

  • Raymond C. Rosen
  • Adam Keller Ashton
Article

Abstract

The search for an effective aphrodisiac has been a perennial pursuit of most societies throughout history. In the past decade, attention has focused increasingly on the prosexual effects of oral pharmacological agents with central neurotransmitter actions. The role of various dopaminergic, adrenergic, and serotonergic agents, in particular, has been intensively investigated in both human and animal studies. Some of these drugs have been considered for their potential role in the treatment of sexual dysfunction, while others have contributed to our understanding of basic neurophysiological processes in sexual arousal. This review provides a critical evaluation of current laboratory and clinical research on the “new aphrodisiacs,” including studies in both patient populations and normal volunteers. Several conceptual and methodological problems are addressed, such as the definition and measurement of sexual response, the need to separate specific and nonspecific drug effects on sexual response, and the lack of studies in women. Although no single drug has proven to be clinically safe and reliably effective for human use, several promising candidates have been identified. Overall, research on prosexual drugs has contributed significantly to our understanding of basic mechanisms in sexual response, as well as providing new treatment options for common sexual disorders.

Key words

aphrodisiac prosexual drug pharmacology neurotransmitter apomorphine yohimbine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Abel, E. L. (1985)Psychoactive Drugs and Sex Plenum Press, New York.Google Scholar
  2. Agmo, A., and Paredes, R. (1985). GABA-ergic drugs and sexual behavior in the male rat.Eur. J. Pharmacol. 112: 371–378.PubMedGoogle Scholar
  3. Ahlenius, S., Larsson, K., and Arvidsson, L. E. (1989). Effects of stereoselective 5-HT-1A agonists on male rat sexual behavior.Pharmacol. Biochem. Behav. 33: 691–695.PubMedGoogle Scholar
  4. Althof, S. E., and Turner, L. A. (1992). Self-injection therapy and external vacuum devices in the treatment of erectile dysfunction. In Rosen, R. C. and Leiblum, S. R. (eds.),Erectile Disorders: Assessment and Treatment, Guilford, New York.Google Scholar
  5. Angrist, B., and Gershon, B. (1976). Clinical effects of amphetamine and L-dopa on sexuality and aggression.Comprehen. Psychiat. 17: 715–722.Google Scholar
  6. Bancroft, J. (1989).Human Sexuality and its Problems Churchill Livingstone, New York.Google Scholar
  7. Bansal, S. (1988). Sexual dysfunction in hypertensive men: A critical review of the literature.Hypertension 12: 1–10.PubMedGoogle Scholar
  8. Beach, F. A. (1942). Analysis of factors involved in the arousol, maintenance, and manifestation of sexual excitement in male animals.Psychosom. Med. 4: 173–198.Google Scholar
  9. Benkert, O., Crombach, G., and Kockott, G. (1972). Effect of L-dopa on sexually impotent patients.Psychopharmacologia 23: 91–95.PubMedGoogle Scholar
  10. Bitran, D., and Hull, E. M. (1987). Pharmacological analysis of male rat sexual behavior.Neurosci. Biobehav. Rev. 11: 365–389.PubMedGoogle Scholar
  11. Bowers, M. B., Van Woert, M., and Davis, L. (1970). Sexual behavior during L-dopa treatment for Parkinsonism.Am. J. Psychiat. 127: 1691–1693.Google Scholar
  12. Brown, E., Brown, G. M., Kofman, O., and Quarrington, B. (1978). Sexual function and affect in Parkinson men treated with L-dopa.Am. J. Psychiat. 135: 1552–1555.PubMedGoogle Scholar
  13. Brown, R. G., Jahanshahi, M., Quinn, N., and Marsden, C. D. (1990). Sexual function in patients with Parkinson's disease and their partners.J. Neurol. Neurosurg. Psychiat. 53: 480–486.PubMedGoogle Scholar
  14. Buffum, J. (1982). Pharmacosexology: The effects of drugs on sexual function.J. Psychoact. Drugs 14: 5–44.Google Scholar
  15. Buffum, J. (1988). Substance abuse and high-risk sexual behavior.J. Psychoact. Drugs 20: 165–168.Google Scholar
  16. Carani, C., Zini, D., Baldini, A., Della Cassa, L., Ghizzani, A., and Marrama, P. (1990). Effects of androgen treatment in impotent men with normal and low levels of free testosterone.Arch. Sex. Behav. 19: 223–234.PubMedGoogle Scholar
  17. Chambers, K. C., and Phoenix, C. H. (1989). Apomorphine, deprenyl, and yohimbine fail to increase sexual behavior in rhesus males.Behav. Neurosci. 103: 816–823.PubMedGoogle Scholar
  18. Clark, J. T., Smith, E. R., and Davidson, J. M. (1984). Enhancement of sexual motivation in male rats by yohimbine.Science 225: 847–849.PubMedGoogle Scholar
  19. Clark, J. T., Smith, E. R., and Davidson, J. M. (1985). Evidence for the modulation of sexual behavior by alpha-adrenoceptors in male rats.Neuroendocrinology 41: 36–43.PubMedGoogle Scholar
  20. Crenshaw, T. L., Goldberg, J. P., and Stern, W. C. (1987). Pharmacologic modification of psychosexual dysfunction.J. Sex Marital Ther. 13 239–253.PubMedGoogle Scholar
  21. Crowe, L. C., and George, W. H. (1989). Alcohol and human sexuality: Review and integration.Psychol. Bull. 105: 374–386.PubMedGoogle Scholar
  22. Danjou, P., Alexandre, L., Warot, D., Lacomblez, L., and Puech, A. J. (1988). Assessment of erectogenci properties of apomorphine and yohimbine in man.Br. J. Clin. Pharmacol. 26: 733–739.PubMedGoogle Scholar
  23. Davidson, J. M., and Rosen, R. C. (1992). Hormonal determinants of erectile function. In Rosen, R. C., and Leiblum, S. R. (eds.),Erectile Disorders: Assessment and Treatment, Guilford, New York.Google Scholar
  24. Dornan, W. A., and Malsbury, C. W. (1989). Neuropeptides and male sexual behavior.Neurosci. Biobehav. Rev. 13: 1–15.PubMedGoogle Scholar
  25. Everitt, B. J. (1990). Sexual motivation: A neural and behavioral analysis of the mechanisms underlying appetitive and copulatory responses of male rats.Neurosci. Biobehav. Rev. 14: 217–232.PubMedGoogle Scholar
  26. Everitt, B. J., and Bancroft, J. (1991). Of rats and men: The comparative approach to male sexuality.Ann. Rev. Sex Res. 2: 77–118.Google Scholar
  27. Foreman, M. M., Hall, J. L., and Love, R. L. (1989). The role of the 5-HT-2 receptor in the regulation of sexual performance of male rats.Life Sci. 45: 1263–1270.PubMedGoogle Scholar
  28. Foreman, M. M., and Wernicke, J. F. (1990). Approaches for the development of oral drug therapies for erectile dysfunction.Semin. Urol. 8: 107–112.PubMedGoogle Scholar
  29. Freed, E. (1983). Increased sexual function with nomifensine.Med. J. Austral. 1: 551.Google Scholar
  30. Gartrell, N. (1986). Increased libido in women receiving trazodone.Am. J. Psychiat. 143: 781–782.PubMedGoogle Scholar
  31. Ghadirian, A. M., Chouinard, G., and Annable, L. (1982). Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients.J. Nerv. Ment. Dis. 170: 463–467.PubMedGoogle Scholar
  32. Gross, M. D. (1982). Reversal by bethanechol of sexual dysfunction caused by anticholinergic antidepressants.Am. J. Psychiat. 139: 1193–1194.PubMedGoogle Scholar
  33. Haslam, M. (1989). Drug treatment of impotence. Presented at the 8th World Congress of Psychiatry. Athens, Greece.Google Scholar
  34. Herman, J. B., Brotman, A. W., Pollack, M. H., Falk, W. E., Biederman, J., and Rosenbaum, J. F. (1990). Fluoxetine-induced sexual dysfunction.J. Clin. Psychiat. 51: 25–27.Google Scholar
  35. Hull, E. M., Bitran, D., Pehek, E. A., Warner, R. K., and Band, L. C., (1984). Intracerebral infusions of oxotremorine affect male sex behavior.Soc. Neurosci. Abstr. 10: 822.Google Scholar
  36. Hull, E. M., Bitran, D., Pehek, E. A., Warner, R. K., Band, L. C., and Holmes, G. M. (1986). Dopaminergic control of male sexual behavior in rats: Effects of an intracerebrally-infused agonist.Brain Res. 370: 73–81.PubMedGoogle Scholar
  37. Hyyppa, M., Falck, S. C., and Rinne, U. K. (1975). Is L-dopa an aphrodisiac in patients with Parkinson's disease? In Sandler, M., and Gessa, G. L. (eds),Sexual Behavior Pharmacology and Biochemistry Plenum Press, New York.Google Scholar
  38. Hyyppa, M., Rinne, U. K., and Sonninen, V. (1970). The activating effect of L-dopa treatment on sexual functions and its experimental background.Acta Neurol. Scand. 46(Supp. 43): 223–224.PubMedGoogle Scholar
  39. Jeanty, P., Van den Kerchove, M., Lowenthal, A., and DeBruyne, H. (1984). Pergolide therapy in Parkinson's disease.J. Neurol. 231: 148–152.PubMedGoogle Scholar
  40. Kaplan, H. S. (1979).Disorders of Sexual Desire New York, Brunner/Mazel.Google Scholar
  41. Klassen, A. D., and Wilsnack, S. C. (1986). Sexual experience and drinking among women in a U.S. national survey.Arch. Sex. Behav. 15: 363–392.PubMedGoogle Scholar
  42. Klein, K. B., Mendels, J., and Lief, H. I. (1987). Drug treatment of patients with inhibited sexual desire: A controlled clinical trial. Presented at the SSTAR annual meeting, New Orleans.Google Scholar
  43. Kline, M. D. (1989). Fluoxetine and anorgasmia.Am. J. Psychiat. 146: 804–805.PubMedGoogle Scholar
  44. Kostis, J. B., Rosen, R. C., Holzer, B. C., Randolph, C., Taska, L. S., and Miller, M. H. (1990). CNS effects of centrally-active antihypertensive agents: A prospective, placebo-controlled study of sleep, mood state, cognitive and sexual function in hypertensive males.Psychopharmacology 102: 163–170.PubMedGoogle Scholar
  45. Kwong, L. L., Smith, E. R., Davidson, J. M., and Peroutka, S. J. (1986). Differential interactions of “prosexual” drugs with 5-hydroxytryptamine1A and alpha-2 adrenergic receptors.Behav. Neurosci. 100: 664–668.PubMedGoogle Scholar
  46. Lal, S., Ackman, D., Tharundayil, J. X., Kiely, M. E., and Etienne, P. (1984). Effects of apomorphine, a dopamine receptor against, on penile tumescence in normal subjects.Prog. Neurol. Psychopharmacol. Biol. Psychiat. 8: 695–699.Google Scholar
  47. Lal, S., Laryea, E., Tharundayil, J. X., Vasavan Nair, N. P., Negrette, J., Ackman, D., Blundell, P., and Gardiner, R. (1987). Apomorphine induced penile tumescence in impotent patients—preliminary findings.Prog. Neurol. Psychopharmacol. Biol. Psychiat. 11: 235–242.Google Scholar
  48. Lal, S., Rios, O., and Thavundayil, J. X. (1990). Treatment of impotence with trazodone: A case report.J. Urol. 143: 819–820.PubMedGoogle Scholar
  49. Lal, S., Tesfaye, Y., Tharundayil, J. X., Thompson, T. R., Kiely, M. E., Vasavan, N. P., Grassino, A., and Dubrovsky, B. (1989). Apomorphine: Clinical studies on erectile impotence and yawning.Prog. Neurol. Psychopharmacol. Biol. Psychiat. 13: 329–339.Google Scholar
  50. Lee, R. L., Smith. E. R., Mas, M., and Davidson, J. M. (1990). Effects of intrathecal administration of 8-OH-DPAT on genital reflexes and mating behavior in male rats.Physiol. Behav. 47: 665–669.PubMedGoogle Scholar
  51. Levine, S. B. (1988). Intrapsychic and individual aspects of sexual desire. In Leiblum, S. R., and Rosen, R. C. (eds.),Sexual Desire Disorders, Guilford, New York.Google Scholar
  52. Margolis, R., Prieto, P., Stein, L., and Chinn, S. (1971). Statistical summary of 10,000 male cases using afrodex in the treatment of impotence.Curr. Ther. Res. 13: 616–621.PubMedGoogle Scholar
  53. Masters, W. H., and Johnson, V. E. (1966).Human Sexual Response. Boston: Little Brown.Google Scholar
  54. McLean, J. D., Forsythe, R. G., and Kapkin, I. A. (1983). Unusual side effects of clomipramine associated with yawning.Can. J. Psychiat. 28: 569–570.Google Scholar
  55. Modell, J. G. (1989). Repeated observations of yawning, clitoral engorgement, and orgasm associated with fluoxetine administration.J. Clin. Psychopharmacol. 9: 63–65.PubMedGoogle Scholar
  56. Monteiro, W. O., Noshirvani, H. F., Marks, I. M., and Lelliott, P. T. (1987). Anorgasmia from clomipramine in obsessive-compulsive disorder: A controlled trial.Br. J. Psychiat. 151: 107–112.Google Scholar
  57. Morales, A., Condra, M., Owen, J. A., Surridge, D. H., Fenemore, J., and Harris, C. (1987). Is yohimbine effective in the treatment of organic impotence? Results of a controlled trial.J. Urol. 137: 1168–1172.PubMedGoogle Scholar
  58. Morales, A., Surridge, D. H., and Marshall, P. G. (1981). Yohimbine for treatment of impotence in diabetes.New Engl. J. Med. 305: 1221.Google Scholar
  59. Othmer, E., and Othmer, S. C. (1987). Effect of buspirone on sexual dysfunction in patients with generalized anxiety disorder.J. Clin. Psychiat. 48: 201–203.Google Scholar
  60. Pfaus, J. G., and Gorzalka, B. (1987). Opioids and sexual behavior.Neurosci. Biobehav. Rev. 11: 1–34.PubMedGoogle Scholar
  61. Pfaus, J. G., and Phillips, A. G. (1989). Differential effects of dopamine receptor antagonists in sexual behavior of male rats.Psychopharmacology 98: 363–368.PubMedGoogle Scholar
  62. Poloniecki, J., and Hamilton, M. (1985). Subjective costs of antihypertensive treatment.Hum. Toxicol. 4: 287–291.PubMedGoogle Scholar
  63. Ricaurte, G. A., Molliver, M. E., Martello, M. B., Katz, J. L., Wilson, M. A., Martello, A. L., and Wilson, M. A. (1991). Dexfenfluramine neurotoxicity in brains of nonhuman primates.Lancet 338: 1487–1488.PubMedGoogle Scholar
  64. Rosen, R. C. (1991). Alcohol and drug effects on sexual response: Human experimental and clinical studies.Ann. Rev. Sex Res. 2: 119–179.Google Scholar
  65. Rosen, R. C., and Beck, J. G. (1988). Patterns of sexual arousal:Psychophysiological Processes and Clinical Applications, Guilford, New York.Google Scholar
  66. Rosen, R. C., and Hall, E. (1984).Sexuality Random House, New York.Google Scholar
  67. Rosen, R. C., and Leiblum, S. R. (1989). Assessment and treatment of desire disorders. In Leiblum, S. R., and Rosen, R. C. (eds.),Principles and Practice of Sex Therapy: Update for the 1990's, Guilford, New York.Google Scholar
  68. Scatton, B., Zivkovic, B., and Dedek, J. (1980). Antidopaminergic properties of yohimbine.J. Pharmacol. Exp. Ther. 215: 494–499.PubMedGoogle Scholar
  69. Scher, M., Krieger, J., and Jurgens, S. (1983). Trazodone and priapism.Am. J. Psychiat. 140: 1362–1363.PubMedGoogle Scholar
  70. Schiavi, R. C. (1990). Chronic alcoholism and male sexual dysfunction.J. Sex Mar. Ther. 16: 23–33.Google Scholar
  71. Schlatter, E. K., and Lal, S. (1972). Treatment of alcoholism using Dent oral apomorphine method.Quart. J. Stud. Alc. 33: 430–436.Google Scholar
  72. Segraves, R. T. (1987). Reversal by bethanacol of impramine-induced ejaculatory dysfunction.Am. J. Psychiat. 144: 1243–1244.Google Scholar
  73. Segraves, R. T. (1989). Effects of psychotropic drugs on human erection and ejaculation.Arch. Gen. Psychiat. 46: 275–284.PubMedGoogle Scholar
  74. Segraves, R. T., Bari, M., Segraves, K., and Spirmak, P. (1991). Effect of apomorphine on penile tumescence in men with psychogenic impotence.J. Urol. (in press).Google Scholar
  75. Smith, P. J., and Talbert, R. L. (1986). Sexual dysfunction with antihypertensive and antipsychotic agents.Clin. Pharm. 5: 373–384.PubMedGoogle Scholar
  76. Sobotka, J. J. (1969). An evaluation of Afrodex in the management of male impotency: A double-blind crossover study.Curr. Ther. Res. 11: 87–94.PubMedGoogle Scholar
  77. Sonda, L. P. Mazo, R., and Chancellor, M. B. (1990). The role of yohimbine for the treatment of erectile impotence.J. Sex Marital Ther. 16: 15–22.PubMedGoogle Scholar
  78. Sorscher, S. M., and Dilsaver, S. C. (1986). Anti-depressant induced sexual dysfunction in men: Due to cholinergic blockade?J. Clin. Psychopharmacol. 6: 53–55.PubMedGoogle Scholar
  79. Steers, W. D. (1990). Neural control of penile erection.Sem. Urol. 8: 66–79.Google Scholar
  80. Steers, W. D., and DeGroat, W. C. (1990). Effects of m-chlorophenyl-piperazine on penile and bladder function in rats.Am. J. Physiol. 257: 1441–1449.Google Scholar
  81. Stevenson, R. W. D., and Solyom, L. (1990). The aphrodisiac effect of fenfluramine: Two case reports of a possible side effect to the use.J. Clin. Psychiat. 10: 69–71.Google Scholar
  82. Sullivan, G. (1988). Increased libido in three men treated with Trazodone.J. Clin. Psychiat. 49: 202–203.Google Scholar
  83. Susset, J. G., Tessier, C. D., Wincze, J., Bansal, S., Malhotra, C., and Schwacha, M. G. (1989). Effect of yohimbine hydrochloride on erectile impotence: A double-blind study.J. Urol. 141: 1360–1363.PubMedGoogle Scholar
  84. Tennent, G., Bancroft, J., and Cass, J. (1974). The control of deviant sexual behavior by drugs: A double-blind controlled study of benperidol, chlorpromazine, and placebo.Arch. Sex. Behav. 3: 261–271.PubMedGoogle Scholar
  85. Tiefer, L. (1991). Historical, scientific, clinical and feminist criticisms of “the human sexual response cycle” model.Ann. Rev. Sex Res. 2: 1–24.Google Scholar
  86. Uitti, R. J., Tanner, C. M., Rajput, A. H., Goetz, C. G., Klawans, H. L., and Thiessen, B. (1989). Hypersensitivity with antiparkinsonian therapy.Clin. Neuropharmacol. 12: 375–383.PubMedGoogle Scholar
  87. Warner, M. D., Peabody, C. A., and Whiteford, H. A. (1987). Trazodone and priapism.J. Clin. Psychiat. 48: 244–245.Google Scholar
  88. Ware, J. C., Pittard, J. T., Nadig, P. W., Morrison, J. L., and Quinn, J. B. (1987). Trazadone: Its effects on nocturnal penile tumescence.Sleep Res. 16: 157.Google Scholar
  89. Ware, J. C., Rose, V., and McBrayer, R. (1991). The effects of nefazodone, trazodone, buspirone, and placebo on sleep and sleep related penile erections (NPT) in normal subjects.Sleep Res. 20: 91.Google Scholar
  90. Wilson, G. T. (1981). The effects of alcohol on human sexual behavior.Adv. Substance Abuse 2: 1–40.Google Scholar
  91. Yager, J. (1986). Bethanechol chloride can reverse erectile and ejaculatory dysfunction induced by tricyclic antidepressants and mazindol: Case report.J. Clin. Psychiat. 47: 210–211.Google Scholar

Copyright information

© Plenum Publishing Corporation 1993

Authors and Affiliations

  • Raymond C. Rosen
    • 1
  • Adam Keller Ashton
    • 2
  1. 1.Department of PsychiatryUniversity of Medicine and Dentistry of New Jersey—Robert Wood Johnson Medical SchoolPiscatawayUSA
  2. 2.School of MedicineState University of New York at BuffaloUSA

Personalised recommendations